



# Pharmacy & Therapeutics Committee

## Meeting Minutes

Thursday, May 19, 2022  
7:00 a.m. to 8:45 a.m.  
Google Meet

### Committee Members Present:

Cole Sloan, PharmD	McKay Robinson, PharmD
Bryan Larson, PharmD	Michelle Hofmann, MD
Clayton Grace, RPh	Susan Siegfried, MD
Clinton Sheffield, MD	

### Committee Members Excused:

Christopher Valentine, MD

### Office of Healthcare Policy and Authorization Staff Present:

Craig Hummel, MD	Katie Gilliland, CPhT
Joe Busby, RPh, MBA	Spencer Miller, CPhT
Luis Moreno, PharmD	Jennifer Strohecker, Medicaid Director
Ngan Huynh, PharmD	Trevor Smith
Stephanie Byrne, PharmD	James Stamos
Andrea Rico, CPhT	

### University of Utah Drug Regimen Review Center Staff Presenter:

Lauren Heath, PharmD

### Other Individuals Present:

Alexis Timpson	Lisa Ashton, Johnson & Johnson
Amy Breen, Teva	Madeline Shurtleff, Otsuka
Becky Gonzales, ViiV	Matt Mitchell, SelectHealth
Beth W (No other info provided)	Matthew Call, UUHP
Bobby White	Mike Eaton, SelectHealth
Bradley Hawkes, Lilly Inc	Monet Luloh, UofU DRRC
Carrie Johnson, Amgen	Natalie Rose, Gilead
Chris (No other info provided)	Robert Nohavec, UUHP
Gary Parenteau, Dexcom	Roy Lindfield, Sunovion
Haley Bruce, Artia Solutions	Samantha Eshelman, SelectHealth
Heidi Goodrich, Molina	San Tran, Health Choice
Jennifer Shear, Teva	Shannon Gilreath, HealthyU

# Pharmacy & Therapeutics Committee

## Meeting Minutes

Katool Springston, Amgen  
 Lauren Heath, UofU DRRC  
 Lee Stout, Chiesi USA

Lindsey Walter, Novartis  
 Valerie Gonzales, UofU DRRC

Meeting conducted by: Cole Sloan

---

1. **Welcome:** Bryan Larson announced a Quorum. Cole Sloan opened the meeting.
2. **Review and Approval of February Minutes:** McKay Robinson made a motion to approve the minutes from February. Clayton Grace seconded the motion. All in favor, motion passed.
3. **Housekeeping:** Bryan Larson reminded attendees to put their name and affiliation in the meeting chat or email [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov).
4. **Drug Utilization Review (DUR) Board update:** Ngan Huynh presented the DUR board update. The DUR board met in April to discuss guidelines for treatment of low back pain. The DUR board met last week to discuss the prior authorization criteria for Tezspire (Tezepelumab) and Hetlioz (tasimelteon).
5. **Accountable Care Organization (ACO) Update:** Report on Methodologies for Preferred Drug List Development:
  - a. Molina ..... Heidi Goodrich, PharmD
  - b. SelectHealth ..... Matt Mitchell, PharmD
  - c. Health Choice ..... San Tran, PharmD
  - d. HealthyU ..... Shannon Gilreath, PharmD
6. **Colony Stimulating Factors:** Presented by Lauren Heath, PharmD from the University of Utah.
  - a. Short-acting Granulocyte-CSF (G-CSF)
    1. Filgrastim, biosimilars filgrastim-aafi (Nivestym), filgrastim-ayow (Releuko), filgrastimsndz (Zarxio), and Tbo-filgrastim.
      1. Used once or twice daily
      2. For all ages
  - b. Long-acting Granulocyte-CSF (G-CSF)

# Pharmacy & Therapeutics Committee

## Meeting Minutes

1. Includes Pegfilgrastim (Neulasta) and biosimilars pegfilgrastim-jmdb (Fulphila), pegfilgrastim-apgf (Nyvepria), pegfilgrastim-cbqv (Udenyca), pegfilgrastim-bmez (Ziextenzo)
  1. Used less frequently (e.g., once per chemotherapy cycle); fixed dose except for weight <45 kg.
  2. For all ages
- c. Granulocyte-Macrophage CSF (GM-CSF)
  1. Sargramostim (Leukine)
    1. Daily use
    2. Age for use varies per FDA-indication
- d. FDA-Approved Indications:

To reduce neutropenic sequelae among patients with:

  1. Nonmyeloid malignancies receiving myelosuppressive chemotherapy
  2. AML receiving induction/consolidation chemotherapy
  3. Nonmyeloid malignancy receiving chemotherapy and a BMT
  4. Severe chronic neutropenia disorders

To mobilize hematopoietic progenitor cells for autologous stem cell collection

  1. All short-acting G-CSFs except for tbo-filgrastim and Releuko

Treatment of hematopoietic syndrome of acute radiation

  1. Filgrastim and pegfilgrastim originators only, for now.
- e. FDA-APPROVED INDICATIONS: SARGRAMOSTIM
  1. To reduce neutropenic sequelae after induction chemotherapy for AML (age = 55 years)
  2. To mobilize hematopoietic progenitor cells for autologous stem cell collection (adults)
  3. Treatment of hematopoietic syndrome of acute radiation
  4. To accelerate myeloid reconstitution after:
    1. Autologous PBSCT or BMT in patients with NHL, Hodgkin's lymphoma or ALL (age = 2 years)

# Pharmacy & Therapeutics Committee

## Meeting Minutes

2. Allogeneic BMT from matched related donor (age = 2 years)
  5. To treat delayed neutrophil recovery or graft failure after an allo- or auto-BMT (age = 2 years)
  - f. **SELECTED GUIDELINE RECOMMENDATIONS**
    1. G-CSFs are recommended to reduce the risk of FN in high-risk oncology patients receiving myelosuppressive chemotherapy
      1. Guidelines are primarily targeted at patients with solid tumors or lymphoma (NCCN – adults)
      2. High-risk: FN incidence = 20%; consider drug + other risk factors
      3. Includes primary or secondary prophylaxis
      4. Short- or long-acting G-CSFs are an option
    2. Other potential uses generally align with FDA-indications, with some off-label uses
7. **Public Comment:**
- a. Carrie Johnson from Amgen presented on Neulasta Onpro.
  - b. Jennifer Shear from Teva presented on Granix.
8. **Committee Discussion:**
- a. Cole Sloan made a motion to have at least one short acting G-CSF that is equally safe and efficacious for their approved indication on the Preferred Drug List. Clayton Grace seconded. All in favor, motion passed. Michelle Hofmann was not present for this vote.
  - b. Cole Sloan made a motion to have at least one long acting G-CSF that is equally safe and efficacious for their approved indication on the Preferred Drug List. Clayton Grace seconded. All in favor, motion passed. Michelle Hofmann was not present for this vote.
  - c. Susan Siegfried made a motion to include grandfathering with a 90 day lookback for individuals on either short-acting or long-acting G-CSF; that they may continue their current medication even if it is not preferred on the Preferred Drug List. Bryan Larson seconded. All in favor, motion passed. Michelle Hofmann was not present for this vote.
9. **Public Meeting Adjourned:** Cole Sloan motioned to close the meeting.



# Pharmacy & Therapeutics Committee

## Meeting Minutes

Bryan Larson seconded the motion. All approved, motion passed.

10. Next meeting is scheduled for September 15, 2022. Topic TBD.

---

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>